Cite
Charokopou M, Vioix H, Verheggen BG, et al. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value Health. 2014;17(7):A343doi: 10.1016/j.jval.2014.08.690.
Charokopou, M., Vioix, H., Verheggen, B. G., Dillon, S., & Franks, D. (2014). Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A343. https://doi.org/10.1016/j.jval.2014.08.690
Charokopou, M, et al. "Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A343. doi: https://doi.org/10.1016/j.jval.2014.08.690
Charokopou M, Vioix H, Verheggen BG, Dillon S, Franks D. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.690. Epub 2014 Oct 26. PMID: 27200640.
Copy
Download .nbib
